SG11202012787PA - Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof - Google Patents
Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereofInfo
- Publication number
- SG11202012787PA SG11202012787PA SG11202012787PA SG11202012787PA SG11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA SG 11202012787P A SG11202012787P A SG 11202012787PA
- Authority
- SG
- Singapore
- Prior art keywords
- dihydroquinolin
- cyclobutoxy
- methanone
- pyrazol
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862692554P | 2018-06-29 | 2018-06-29 | |
US201862692546P | 2018-06-29 | 2018-06-29 | |
PCT/US2019/039677 WO2020006329A1 (en) | 2018-06-29 | 2019-06-28 | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012787PA true SG11202012787PA (en) | 2021-01-28 |
Family
ID=68984963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012787PA SG11202012787PA (en) | 2018-06-29 | 2019-06-28 | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210261528A1 (en) |
EP (1) | EP3813835A4 (en) |
JP (1) | JP2021529764A (en) |
KR (1) | KR20210025615A (en) |
CN (1) | CN112584835A (en) |
AU (1) | AU2019293260A1 (en) |
BR (1) | BR112020026359A2 (en) |
CA (1) | CA3103153A1 (en) |
IL (1) | IL279673A (en) |
MX (1) | MX2020013636A (en) |
SG (1) | SG11202012787PA (en) |
WO (1) | WO2020006329A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021003163A1 (en) | 2019-07-01 | 2021-01-07 | Forma Therapeutics, Inc. | Treating cancer with a bromodomain and extra-terminal (bet) family inhibitor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012508215A (en) * | 2008-11-11 | 2012-04-05 | ノバルティス アーゲー | Organic compounds |
AU2014348191B2 (en) * | 2013-11-18 | 2019-03-28 | Forma Therapeutics Inc. | Tetrahydroquinoline compositions as BET bromodomain inhibitors |
US20160256448A1 (en) * | 2013-11-18 | 2016-09-08 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
-
2019
- 2019-06-28 AU AU2019293260A patent/AU2019293260A1/en not_active Abandoned
- 2019-06-28 WO PCT/US2019/039677 patent/WO2020006329A1/en active Application Filing
- 2019-06-28 EP EP19824492.3A patent/EP3813835A4/en not_active Withdrawn
- 2019-06-28 BR BR112020026359-1A patent/BR112020026359A2/en not_active Application Discontinuation
- 2019-06-28 JP JP2020573228A patent/JP2021529764A/en active Pending
- 2019-06-28 CA CA3103153A patent/CA3103153A1/en active Pending
- 2019-06-28 MX MX2020013636A patent/MX2020013636A/en unknown
- 2019-06-28 US US17/255,054 patent/US20210261528A1/en not_active Abandoned
- 2019-06-28 SG SG11202012787PA patent/SG11202012787PA/en unknown
- 2019-06-28 KR KR1020217002541A patent/KR20210025615A/en unknown
- 2019-06-28 CN CN201980054832.2A patent/CN112584835A/en active Pending
-
2020
- 2020-12-22 IL IL279673A patent/IL279673A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112020026359A2 (en) | 2021-03-30 |
CN112584835A (en) | 2021-03-30 |
KR20210025615A (en) | 2021-03-09 |
JP2021529764A (en) | 2021-11-04 |
WO2020006329A1 (en) | 2020-01-02 |
EP3813835A1 (en) | 2021-05-05 |
CA3103153A1 (en) | 2020-01-02 |
IL279673A (en) | 2021-03-01 |
MX2020013636A (en) | 2021-03-25 |
AU2019293260A1 (en) | 2021-01-07 |
EP3813835A4 (en) | 2022-03-02 |
US20210261528A1 (en) | 2021-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11202100410YA (en) | Splittable security token | |
IL248924A0 (en) | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor | |
EP3351122A4 (en) | Mouth piece of electronic cigarette, e-liquid cartridge, and electronic cigarette | |
RS62082B1 (en) | Imidazolonyl quinolines and their use as atm kinase inhibitors | |
IL247833B (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
EP3376865A4 (en) | 4-((6-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h | |
IL247832A0 (en) | 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation | |
IL236922A0 (en) | Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
HK1258996A1 (en) | Methods, compositions, and uses of novel fyn kinase inhibitors | |
SG11201600996UA (en) | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
IL270753A (en) | Nanopore sequencers | |
IL291181A (en) | Azole-fused pyridazin-3(2h)-one derivatives | |
IL279673A (en) | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof | |
SG11201809760TA (en) | Novel 2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof | |
EP3553059A4 (en) | Hydrobromate of benzodiazepine derivative, preparation method and use thereof | |
HK1254741A1 (en) | (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate | |
EP3233824A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
EP3554499A4 (en) | Aminopyrazoles as janus kinase inhibitors | |
EP3233079A4 (en) | (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations | |
EA202190154A1 (en) | SALTS (S) - (5-CYCLOBUTOXI-2-METHYL-6- (1- (PIPERIDIN-4-YL) -1H-PYRAZOL-4-YL) -3,4-DIHYDROQUINOLIN-1 (2H) -YL) ( CYCLOPROPYL) METHANONE AND ITS SOLID FORMS | |
EP3264852A4 (en) | Method for allocating ip address in d2d communication, and user equipment | |
IL257734B (en) | 1-(cyclopropylmethyl)-4-(3,3,3-trifluoropropanoyl) octahydro-1h-2,6-methanopyrrolo[3,2-b]pyridin-3-yl pivalates and synthesis thereof | |
EP3545951A4 (en) | Oral tablet composition comprising dexlansoprazole, oral tablet comprising same and method for manufacturing same | |
HK1226182A1 (en) | Method for providing request information and user terminal | |
PL3153022T3 (en) | N-(3',4'-dichlor-5-methoxybiphenyl-2-yl)-3-(difluormethyl)-1-methyl-1h-pyrazol-4-carboxamide |